Fiche centre
Inha University Hospital
Incheon — South Korea
Essais liés9clinical trials
VilleIncheonlocalisation
PaysSouth Korealocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07064473
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| RO7126209 | Alzheimer | Phase 1/2 | NCT04639050 | Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| ACP-204 | Alzheimer | Phase 2/3 | NCT06159673 | ACP-204 in Adults With Alzheimer's Disease Psychosis | RECRUITING |
| Xanomeline/Trospium Chloride Capsule | Alzheimer | Phase 3 | NCT07011745 | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease | RECRUITING |
| Vicadrostat | Hypertension | Phase 3 | NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | RECRUITING |
| ACP-204 | Alzheimer | Phase 3 | NCT06194799 | ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study | ENROLLING_BY_INVITATION |
| Donanemab | Alzheimer | Phase 2 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07170150 | TRONTIER 2 — A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | RECRUITING |
| Participants receive Neuclare Device while continuing their cognitive medication | Alzheimer | Non applicable | NCT07239310 | Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease | RECRUITING |
| RO7269162 | Alzheimer | Phase 2 | NCT06402838 | A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | ACTIVE_NOT_RECRUITING |